Clinical Trial Update: Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Efavaleukin Alfa in Participants With Systemic Lupus Erythematosus [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating safety, tolerability, PK/PD, and immunogenicity of efavaleukin alfa in systemic lupus erythematosus has completed with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• Efavaleukin Alfa (efavaleukin alfa)

Snippet

Sponsor: Amgen | Conditions: Systemic Lupus Erythematosus | Phase 1 | Status: COMPLETED | Results posted: 2023-07-19